sexta-feira, 6 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 23, 2026

The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now

View original at nasdaq.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now Key Points Wall Street analysts love these two artificial intelligence (AI) stocks…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Applied Digital is targeting $1 billion in net operating income (NOI) over the next five years

    60% confidence
  • Interest is high among hyperscalers for all of these new facilities

    60% confidence
  • If you invested $1,000 in Netflix on December 17, 2004, you'd have $502,837

    60% confidence
  • Roughly 93% of the 70 analysts who cover Nvidia say it is a buy with a median price target of $267.50, suggesting about 33% upside

    60% confidence
  • Stock Advisor's total average return is 977% compared to 200% for the S&P 500

    60% confidence
  • If you invested $1,000 in Nvidia on April 15, 2005, you'd have $1,241,433

    60% confidence
  • 100% of the 13 analysts that cover Applied Digital rate it a buy, with a median price target of $43 per share, suggesting 32% upside

    60% confidence
  • Some $4 trillion is projected to be spent on data centers in 2030 worldwide, up from $1 trillion in 2025

    60% confidence

Data points we hold from this source

S&P 500 · return200 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now — Source | Via News | pt.VIA.NEWS